The role of red blood cell exchange in sickle cell disease in patient with COVID-19 infection and pulmonary infiltrates

Lina Okar | Maya Aldeeb | Mohamed A. Yassin

1Department of Medical Education, Hamad Medical Corporation, Doha, Qatar
2Department of Medical Oncology, Hematology Section, National Center for Cancer Care & Research, Hamad Medical Corporation, Doha, Qatar

Correspondence
Lina Okar, Family Medicine Department, Hamad Medical Corporation, Al Rayan Street, Doha, PO Box 3050, Qatar.
Email: linaokar227@gmail.com

Funding information
Qatar Foundation

Abstract
Due to the overlap between ACS and COVID-19 pneumonia, we recommend close monitoring for those patients and offering them RBC exchange early in the course of the disease to avoid clinical deterioration.

KEYWORDS
acute chest syndrome, COVID-19, hemoglobinopathies, red blood cell exchange, Sickle cell disease

1 | INTRODUCTION
COVID-19–related pneumonia overlaps with ACS, one of the most common acute presentations in SCD patients. We present a case of 22-year-old SCD patient presented to the emergency department with mild respiratory symptoms turned out to be COVID-19 positive and received red blood cell exchange to avoid the possibility of deterioration.

COVID-19 also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel virus that caused the latest pandemic in the world. The most serious presentation of this virus was acute respiratory distress syndrome (ARDS) which has high mortality rate. Elderly patient and those with multiple comorbidities have been categorized as high-risk group for developing serious complication from COVID-19 infection.

SCD is one of the most common hemoglobinopathies worldwide, and it affects the shape of red blood cells (RBCs) which leads to several clinical manifestations. Complications might be acute or chronic, and the most important and common acute complications are vaso-occlusive crisis (VOC) and acute chest syndrome (ACS). Respiratory infections are considered an important trigger for ACS. The impact of COVID-19 infection in SCD patients is still not clear, and data are conflicting. However, some experiences suggested low mortality and morbidity rate in SCD patients with COVID-19 infection. Previously published researches mentioned the overlap between COVID-19 pneumonia and ACS which we believed rises a challenge for physician, and thus, we recommend that those patients should be monitored closely as deterioration in their clinical status was prescribed in multiple case reports. The definitive management plan in this situation is not defined clearly till now. Whether applying early red blood cell exchange can prevent further deterioration is still a question that needs to be answered.

2 | CASE PRESENTATION
A 22-year-old man presented to the hospital with history of fever, sore throat, mild nonproductive cough, generalized body ache, chest pain, fatigue, and decreased appetite for...
# Table 1: Investigations

| Investigation                      | Findings                                                                 |
|-----------------------------------|--------------------------------------------------------------------------|
| **Chest X-ray:**                  | Small ill-defined patchy opacity is seen at right lung lower zone periphery, differential diagnosis includes viral infection. |
| Figure 1.                         | Clear both costophrenic angles.                                          |
|                                  | Normal cardio-thoracic ratio.                                            |
| **ECG**                           | Corrected QT: 379 ms, no signs of ischemic change, normal QRS and ST segment. |
| **Blood tests:**                  |                                                                          |
| **ABO**                           | Group B +                                                                |
| Hemoglobin                        | 12.8                                                                     |
| (13-17 gm/dL)                     |                                                                          |
| RBCs (4.5-5.5 x 10^{6})           | 4.0                                                                      |
| WBCs (4-10 x 10^{3}/UL)           | 3.2                                                                      |
| ANC (2.0-7.0 x 10^{3}/UL)         | 1.76                                                                    |
| PLT (150-400 x 10^{3}/UL)         | 77                                                                       |
| Reticulocyte (0.2%-2.5%)          | 1.1                                                                      |
| Lymphocytes count (1-3 x 10^{3}/UL)| 1.03                                                                     |
| Ferritin (8-252 mcg/L)            | 608 (comparing with 49 last value)                                       |
| IL6 (6 - 9 pg/mL)                 | 9                                                                        |
| CRP (0-5 Umg/L)                   | 9.5 on admission                                                          |
| D-dimer (0.00 –0.4 mcg/L)         | 2 on discharge                                                            |
| LDH (135-214 U/L)                 | 199                                                                      |
| Renal function tests (Urea/ Cr)   | Ur 2                                                                    |
| (2.1 - 8.8mmol/L)                 | Cr 67                                                                    |
| (44- 80Umoll/L)                   |                                                                          |
| ALT/ AST                          | 12.6                                                                    |
| (0-33 U/L)                        | 20                                                                       |
| (0-32 U/L)                        |                                                                          |
| TB (0-21 umol/L)                  | 43                                                                       |
| DB (0-5 Umol/L)                   | 11                                                                       |
| Albumin                           | 46                                                                       |
| (35-50 gm/L)                      |                                                                          |
| G6PD                              | Normal                                                                   |
| Hemoglobin electrophoresis        | Hgb A 0.0                                                                |
|                                  | Hgb A2 3.0                                                               |
|                                  | Hgb F 26.9                                                               |
|                                  | Hgb S 70.1                                                               |
| COVID-19 PCR                      | Positive                                                                 |
| Outcome                           | Favorable                                                                |
three days. The patient has history of sick contact history with an a positive COVID-19 case, no recent travel. His past medical history was remarkable for non-transfusion dependent Sickle cell disease taking Hydroxyurea 500 mg daily, no previous surgeries, previous recurrent painful crisis most of them did not require hospital admission and presented as generalized pain, pain in the right arm and left hip which appeared to be avascular necrosis, last painful crisis was 7 months before as lower limb pain for which he was given only tramadol. Primary investigations including laboratory tests, nasopharyngeal swab for COVID-19 PCR, and chest X-ray were performed, and the results are shown in Table 1.

To this point, the patient differential diagnosis was as follows: Acute chest syndrome triggered with COVDI-19 infection or viral pneumonitis. He was admitted to the intensive care unit (ICU) after considering him as high risk for COVID-19 complication. The decision was made to do red blood cell exchange early in the course of the infection to avoid possible deterioration in his case and the need of intubation. Upon admission to the ICU, his vital signs were as follows: temperature 36.4, heart rate 69/min, respiratory rate 20/min, blood pressure 117/59 mm Hg, and oxygen saturation of 96% on room air, and he did not require any oxygen supplementation in ICU. He was on the following medications: Lopinavir/ Ritonavir (Kaletra) 200/50 mg for two days which later stopped and cefuroxime 1.5 g daily was given for 7 days, Hydroxyurea 500 mg daily, and enoxaparin 40 mg SC as thrombosis prophylaxis, although he had thrombocytopenia the benefit from offering him thrombosis prophylaxis outweigh the risk of bleeding. Plasma exchange with 6 units of PRBCs was done on the second day of hospital admission without any complications. He stayed in the ICU for 4 days for observation and then transferred to the ward; during ICU admission, no deterioration was happened, and in the ward, repeated chest X-ray was normal. After 6 days in the ward without any deterioration in his clinical course with resolving respiratory symptoms, the patient was discharged to a quarantine facility (Figure 1).

3 | DISCUSSION

Coronavirus is the novel virus responsible for the latest pandemic declared by World Health Organization (WHO) on March 11, 2019. Taking a good history to define the risk of infection is critical as patient might be asymptomatic. However, symptomatic patients may present with fever, dyspnea, Che, fatigue, and generalized muscle ache. Other non-typical symptoms like gastrointestinal were also reported. Severity of the disease differs among affected patients for example elderly, and patients with comorbidities like hypertension, diabetes, and cardiovascular diseases are at more risk for complication and worse clinical course than normal population.

Sickle cell disease (SCD) is an inherited hemoglobinopathy with main characteristic being the presence of hemoglobin S (HbS). The inheritance might be in homozygous or heterozygous form with a disease severity that differs accordingly. This hemoglobin causes deformity in the structure of red blood cells (RBCs) changing them to sickle-shaped, rigid, and dysfunctional RBCs. Clinical manifestations are vaso-occlusive crisis (VOC), intra- and extra-vascular hemolytic anemia. Complication of SCD can be categorized into acute and chronic.

Acute complications include acute chest syndrome (ACS), vaso-occlusive crisis (VOC), hepatobiliary complications, stroke, splenic sequestration, priapism, acute anemia, and fever. Chronic complications are pulmonary hypertension, hepatic iron overload, kidney disease, avascular necrosis, retinopathy, and legs ulcer. Among the acute complications, the most common are VOC and ACS. VOCs are episodes of severe pain due to microvascular occlusion with erythrocytes and leukocytes, thus preventing blood flow and causing organ ischemia. ACS is common lung insult in SCD patients, known as newly pulmonary infiltrate due to alveolar consolidation affecting one lung segment at least, in it is severe form it is similar to the acute respiratory distress syndrome (ARDS), along with the radiological findings, patients usually present with fever, chest pain, shortness of
### TABLE 2  Literature review

| Reference | Patient Number | Age | gender | Past medical history | Presenting symptoms | Clinical course | Radiology findings (chest X-ray or CT) | Management | ICU Admission | Length of stay | Outcome |
|-----------|----------------|-----|--------|----------------------|---------------------|-----------------|----------------------------------------|------------|---------------|----------------|---------|
| 1         | 4              | 32  | Male   | Recurrent VOC ACS    | VOC                 | Severe          | Positive                               | Ceftriaxone Azithromycin HDQ Blood transfusion | Yes        | 13 days       | Favorable      |
| 22        | Female         |      |        | Recurrent VOC ACS    | VOC GI symptoms     | Mild            | Negative                               | Ceftriaxone Pain medication                | No         | 2 days        | Favorable      |
| 37        | Female         |      |        | Recurrent VOC ACS    | VOC                 | Mild            | Negative                               | Pain medications                           | No         | 8 days        | Favorable      |
| 41        | Male           |      |        | Avascular necrosis (bilateral hip) | Respiratory symptoms Hip pain (VOC) | Mild | Not available | Pain medications | No | 4 days | Discharged against medical advice |
| 16        | 2              | 24  | Male   | Minor VOC ACS        | Chest pain (ACS)    | Moderate        | Positive                               | Amoxicillin-clavulanate                   | No         | 3 days        | Favorable      |
| 20        | Female         |      |        | Recurrent VOC ACS    | VOC Low oxygen saturation | Moderate | Negative | Pain management                   | No         | NA            | Favorable      |
| 5         | 1              | 21  | Male   | Recurrent VOC ACS    | VOC Fever           | Mild            | positive                               | Ceftriaxone, azithromycin HCQ Blood transfusion Exchange transfusion | NA         | 16 days       | Favorable      |
| 17        | 1              | 45  | Male   | Sickle cell nephropathy | multifocal VOC and fever | severe | positive | Amoxicillin-clavulanic acid HCQ O2 supplementation Tocilizumab and Blood transfusion | No | 5 days | Favorable |
| 15        | 1              | 27  | Male   | VOCs                 | VOC Fever Respiratory symptoms | severe | Positive | Ceftriaxone Doxycycline Piperacillin/tazobactam HCQ Tocilizumab methylprednisolone O2 supplementation Exchange transfusion | Yes | 12 days | Favorable |

(Continues)
| Reference | Patient Number | Age | gender | Past medical history | Presenting symptoms | Clinical course | Radiology findings (chest X-ray or CT) | Management | ICU Admission | Length of stay | Outcome |
|-----------|----------------|-----|--------|---------------------|---------------------|-----------------|----------------------------------------|------------|---------------|----------------|---------|
| 18        | 1              | 35  | Female (Pregnant) | ACSs, Pulmonary thromboembolism, Pulmonary Hypertension, Leg ulcers, preeclampsia in a previous pregnancy | Fever, Myalgia, Respiratory symptoms, Low Oxygen saturation | Severe, positive | O2 supplementation, Ceftriaxone, Azithromycin, Blood transfusion | Yes      | 9 days        | Favorable       |         |
| 19        | 1              | 18  | Female | VOCs, Acute intrahepatic cholestasis | VOC, fever, myalgia, respiratory symptoms, low oxygen saturation | Severe, positive | Azithromycin, Pain medications, Simple transfusion | Yes      | 16 days       | Favorable        |         |
| 20        | 3              | 23  | Female | VOCs, Acute intrahepatic cholestasis | Fever, cough, abdominal pain, weight loss, symptomatic leg ulcer, coughing and slight dyspnea | Mild, positive | Clarithromycin, Exchange transfusion | No       | 2 days        | Favorable        |         |
| 23        | Female         |     |        | NA                  | VOC, AKI, vomiting | Moderate complicated with DVT, positive | Ceftriaxone, Metronidazole, Oxygen supplementation, Enoxaparin, Exchange transfusion | NO       | 51 days       | Favorable        |         |
| 21        | 3              | 14  | Female | VOCs                | VOC                 | Mild, negative | Pain medications, ceftriaxone | No       | 10 days       | Favorable        |         |
| 12        | Male           |     |        | Splenectomy         | VOC                 | Mild initially then severe, negative, initially then repeated positive | Ceftriaxone, Azithromycin, Oxygen supplementation, blood transfusion, dexamethasone, HCQ | No       | 12 days       | Favorable        |         |
| 50        | Female         |     |        | Asymptomatic        | Asymptomatic        | Negative | none | none | none | Favorable | (Continues) |
### Other larger studies:

| Reference | Patient Number | Age (range) | gender | Past medical history | Presenting symptoms | Clinical course | Radiology findings (chest X-ray or CT) | Management | ICU Admission | Length of stay | Outcome |
|-----------|----------------|-------------|--------|----------------------|---------------------|----------------|----------------------------------------|------------|--------------|---------------|---------|
| 22        | 83             | 30 (0.3-68) | 38 Male | 48/83 ACS 44/83 VOC  | 44 VOC 23 ACS       | NA            | 6 simple transfusion 7 exchange transfusion | 17 Admitted 9 intubated 2 ECMO | 8 (2-37) | 2 died |
| 23        | 10             | range, 23-57 | 5 of them recurrent VOC One CKD One stroke Two: iron overload 5 mild 1 severe Fever Dry cough Hypoxemia 8/10 presented with VOC | 8/10 positive 3 needed blood transfusion One severely ill, only palliative treatment One needed peritoneal dialysis | 1 ICU admission | Mean length of stay 7.2 days (range, 3-17) | 9 Favorable 1 death |
| 24        | 24 patients    | <60, >60     | 6 Male 18 Female | 12 HTN 12 obesity 9 DM 3 asthma 3 ESRD 5 malignancy 6 VTE 1 COPD | Fever 79% Cough 83% Myalgia 67% VOCs-4 | NA | 4 blood transfusion HCQ and steroid for all patient 7 required o2 supplementation | 1 ICU admission Mean 7.6 days SCT IN SCD | 1 death |
| 25        | 178            | <19 44 >19 134 | 101 Females 76 Males | 96 recurrent pain crises 57 > 1-episode ACS 23 chronic transfusion 23 PAH 32 Stroke 56 renal disease 11 asymptomatic 96 mild 32 moderate 30 severe 9 critical | 68 blood transfusion 16 Exchange transfusion 4 required dialysis | NA | 19 10 needed intubations | 13 death |
| 4         | 9              | Mean 27.9    | 5 Male 4 Female | 8/9 positive findings | 6 received blood transfusion | 1 Intubation 0 | 0-16 days |

This study suggests the following:
- COVID-19 does not seem to increase the morbidity or mortality in patients with SCD.
- VOC can complicate COVID-19 infection.
- Patients with SCD should be monitored closely during hospitalization as they might deteriorate easily.

4/9 Mean 20.9 5 Male 4 Female 8/9 positive findings 6 received blood transfusion 1 Intubation 0
breath, cough and wheezing. It is considered the second most common cause of hospitalization and the main reason behind intensive care unit admission as well as early death among those patients. There are three previously mentioned causes of ACS: first, pulmonary infection; second, bone marrow fat embolization; and third, intra-vascular pulmonary sequestration. Among those causes, pulmonary infections are the most common one and it is usually due to community-acquired pathogen that causes over-inflammatory response instead of mild upper respiratory picture. The National Acute Chest Syndrome Study published by Vichinsky et al to define the causes of ACS showed that infections are the main cause with atypical bacteria and viruses being the major causes, and despite the splenic dysfunction in SCD, encapsulated bacteria were rarely isolated. 

Patients with hemoglobinopathies are considered high risk for developing severe complication from COVID-19 infection as per the Thalassemia International Federation. However, no strong evidence is available in this regard, and it is not well known if COVID-19 infection really increase the morbidity and mortality in SCD patients or not. The overlap between the ACS and COVID-19 pneumonia has been described. Thus, taking a final decision in this regard is hard because of the conflicting data in literature and variance of COVID-19 clinical course among SCD population, and we summarized all previously published data in Table 2.

As we notice from the table above, few published cases described the use of RBC exchange to manage ACS in SCD patients. Whenever RBCs exchange was used it was because those patients deteriorated, interestingly all of them improved after the exchange that is why we should raise the following question “Is it necessary to leave this choice as a rescue option?” Previously similar published case described the role of early RBCs exchange in preventing further deterioration in SCD patient, in that case they offer RBCs exchange once oxygen requirement started to increase. The difference in our case is that we chose to offer our patient RBC exchange even when he was stable due to the overlapping between ACS and COVID-19 pneumonia, and by weighing the benefit and risk, we believe that giving him RBC exchange played an important role in alleviating the infection course as well as the need of ICU admission and possible intubation.

Both pneumonia and acute chest syndrome are life-threatening conditions. Red blood cell exchange is a well-known method to treat ACS, and there are published data about using it in case of severe COVID-19 pneumonia, mostly after deterioration. Here, we present the first case report for SCD patient infected with COVID-19 who received red blood cell exchange immediately after admission to avoid the deterioration and need of intubation giving him the benefit of doubt. We think offering RBC exchange for patients with SCD and COVID-19 pneumonia upon diagnosis may have major benefits such as avoiding ICU admission and intubation.

4 CONCLUSION

With the latest pandemic due to COVID-19 infection, a lot of patients were vulnerable and at risk of developing severe and fatal complications. Patients with SCD suffer from multiple acute and chronic complications. The exact clinical course of COVID-19 infection in those patients is not yet final, and conflicting data are available. However, delaying appropriate management may carry an increased risk for intubation and mortality. We recommend that physicians should keep a low threshold for admitting SCD patients in whom they suspect COVID-19 infection and to monitor them closely as well provide RBCs exchange initially in the disease course to give them the benefit of doubt. More research is needed to reach a high evidence regarding the management plan.

ACKNOWLEDGMENTS

We would like to acknowledge the hematology section/ oncology department, intensive care unit, and Family Medicine Residency Program at Hamad Medical Corporation for their support. Published with written consent of the patient. Open Access funding provided by the Qatar National Library.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

All authors contributed equally in writing the manuscript.

STATEMENT OF ETHICS

Consent was obtained from the patients. Case was approved by HMC Medical Research Center.

DATA AVAILABILITY STATEMENT

All data related to this article are available upon request.

ORCID

Lina Okar https://orcid.org/0000-0001-7184-1235
Mohamed A. Yassin https://orcid.org/0000-0002-1144-8076

REFERENCES

1. Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020;189:851-852.
2. Pinto VM, Balocco M, Quintino S, Forni GL. Sickle cell disease: a review for the internist. Intern Emerg Med. 2019;14:1051-1064.
3. Gladwin MT, Vichinsky E. T 2254.
4. Ramachandran P, Perisetti A, Kathirvelu B, et al. Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience. EJHaem. 2020;7(9):e632–e634.
5. Beerens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020;95:E154-E156.
6. Down B, Kulkarni S, Khan AHA, Barker B, Tang I. Novel coronavirus (COVID-19) infection: What a doctor on the frontline needs to know. Ann Med Surg. 2020;55:24-29.

7. Soliman AT, Prabhakaran Nair A, Al Masalamani MS, et al. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus non-diabetic symptomatic patients with COVID-19: A comparative study. Acta Biomed. 2020;91:e2020010.

8. Wali Y, Kini V, Yassin MA. Distribution of sickle cell disease and assessment of risk factors based on transcranial Doppler values in the Gulf region. Hematol (United Kingdom). 2020;25:55-62.

9. Yassin M, Soliman A, De Sanctis V, et al. Liver iron content (LIC) in adults with sickle cell disease (SCD): Correlation with serum ferritin and liver enzymes concentrations in transfusion dependent (TD-SCD) and non-transfusion dependent (NT-SCD) patients. Mediterr J Hematol Infect Dis. 2017;9:20.

10. Yassin MA, Soliman AT, de Sanctis V, et al. Statural growth and prevalence of endocrinopathies in relation to liver iron content (LIC) in adult patients with beta thalassemia major (BTM) and sickle cell disease (SCD). Acta Biomed. 2018;89:33-40.

11. Shier A, Abdelrazek M, Soliman A, et al. Short-Term Outcome and MRI Changes in Three Adult Patients with Sickle Cell Disease and Aseptic Osteonecrosis after Treatment with Hyperbaric Oxygen Therapy: A Preliminary Report. Case Rep Oncol. 2020;13:365-372.

12. Abdelmahmuod E, Yassin MA, Ahmed M, Ali E. The Relationship Between Sickle Cell Disease and Sudden Onset Sensorineural Deafness. Cureus. 2020;12(9(1)):e9413.

13. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342:1855-1865.

14. Farmakis D, Giakoumis A, Cannon L, Angastiniotis M, Eleftheriou A. COVID-19 and thalassaemia: A position statement of the Thalassaemia International Federation. Eur J Haematol. 2020;1:9.

15. Allison D, Campbell-Lee S, Crane J, et al. Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease? J Clin Apher. 2020;35:378-381.

16. Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020;95:725-726.

17. De Luna G, Habibi A, Deux JE, et al. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. 2020;95:876-878.

18. Justino CC, Campanharo FF, Augusto MN, de Morais SC, Figueiredo MS. COVID-19 as a trigger of acute chest syndrome in a pregnant woman with sickle cell anemia. Hematol Transfus Cell Ther. 2020;42:212-214.

19. Quaresima M, Quaresima V, Naldini MM, et al. Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS-CoV-2 positivity. EJHaem. 2020;1(1):384-387.

20. Azerad M, Bayoudh F, Weber T, et al. Sickle cell disease and COVID-19: Atypical presentations and favorable outcomes. EJHaem. 2020;1(1):338-341.

21. Al-Hebshi A, Zolaly M, Alshengeti A, et al. A Saudi family with sickle cell disease presented with acute crises and COVID-19 infection. Pediatr Blood Cancer. 2020;67(9):1-9.

22. Arlet JB, de Luna G, Khimoud D, et al. Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol. 2020;7:e632-e634.

23. McCloskey KA, Meenan J, Hall R, Tsitsikas DA. COVID-19 infection and sickle cell disease: a UK centre experience. Br J Haematol. 2020;190:e57-e58.

24. Balanchivadze N, Kudirka AA, Askar S, et al. Impact of COVID-19 Infection on 24 Patients with Sickle Cell Disease. One Center Urban Experience, Detroit, MI, USA. Hemoglobin. 2020;44(4):284-289.

25. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20–May 21, 2020. Emerg Infect Dis. 2020;26(10):2473-2476.